JP2020055853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020055853A5 JP2020055853A5 JP2019221240A JP2019221240A JP2020055853A5 JP 2020055853 A5 JP2020055853 A5 JP 2020055853A5 JP 2019221240 A JP2019221240 A JP 2019221240A JP 2019221240 A JP2019221240 A JP 2019221240A JP 2020055853 A5 JP2020055853 A5 JP 2020055853A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- human
- monoclonal antibody
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908190P | 2013-11-25 | 2013-11-25 | |
| US61/908,190 | 2013-11-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532636A Division JP6879739B2 (ja) | 2013-11-25 | 2014-11-25 | 癌治療のための抗ｃｅａｃａｍ１および抗ｐｄ抗体を含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020055853A JP2020055853A (ja) | 2020-04-09 |
| JP2020055853A5 true JP2020055853A5 (https=) | 2020-12-10 |
Family
ID=53179065
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532636A Active JP6879739B2 (ja) | 2013-11-25 | 2014-11-25 | 癌治療のための抗ｃｅａｃａｍ１および抗ｐｄ抗体を含む組成物 |
| JP2019221240A Pending JP2020055853A (ja) | 2013-11-25 | 2019-12-06 | 癌治療のための抗ｃｅａｃａｍ１および抗ｐｄ抗体を含む組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532636A Active JP6879739B2 (ja) | 2013-11-25 | 2014-11-25 | 癌治療のための抗ｃｅａｃａｍ１および抗ｐｄ抗体を含む組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10081679B2 (https=) |
| EP (2) | EP3763387B1 (https=) |
| JP (2) | JP6879739B2 (https=) |
| KR (1) | KR102362803B1 (https=) |
| CN (1) | CN105744955B (https=) |
| AU (1) | AU2014351308B2 (https=) |
| CA (1) | CA2930218C (https=) |
| ES (2) | ES2808684T3 (https=) |
| HK (1) | HK1225998A1 (https=) |
| MX (1) | MX375221B (https=) |
| PL (2) | PL3763387T3 (https=) |
| RU (1) | RU2697522C1 (https=) |
| WO (1) | WO2015075725A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE033369T2 (en) | 2012-11-20 | 2017-11-28 | Sanofi Sa | Anti-ceacam5 antibodies and uses thereof |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| CN106573977B (zh) | 2014-04-27 | 2020-08-07 | 菲姆威有限公司 | 针对ceacam1的人源化抗体 |
| US11427647B2 (en) * | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| CN106699889A (zh) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技（上海）有限公司 | 抗pd-1抗体及其治疗用途 |
| CN107345969A (zh) * | 2016-05-05 | 2017-11-14 | 中国医学科学院基础医学研究所 | 包含afp、gp73和ceacam1的血清标记物在诊断肝脏疾病中的用途 |
| CN107345968A (zh) * | 2016-05-05 | 2017-11-14 | 中国医学科学院基础医学研究所 | Cecam1蛋白作为血清标记物在诊断肝脏疾病中的用途 |
| EP3560957A4 (en) | 2016-11-14 | 2020-10-21 | Dinona | ANTIBODIES BINDING SPECIFICALLY TO CD66C AND ASSOCIATED USE |
| JP7106538B2 (ja) | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
| CN106957823A (zh) * | 2016-12-28 | 2017-07-18 | 无锡傲锐东源生物科技有限公司 | 抗pd‑l2蛋白单克隆抗体及其用途 |
| KR102019913B1 (ko) * | 2017-03-24 | 2019-09-09 | 재단법인 목암생명과학연구소 | 항-ceacam1 항체 및 이의 용도 |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| JP2022513729A (ja) * | 2018-12-07 | 2022-02-09 | ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイティド | ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体 |
| JP2022514615A (ja) * | 2018-12-20 | 2022-02-14 | アルバート アインシュタイン カレッジ オブ メディスン | ヒト免疫チェックポイントＣＥＡＣＡＭ１（ＣＤ６６ａ）に対するアンタゴニスト抗体及びその製剤、キット並びに使用方法 |
| KR102166982B1 (ko) * | 2019-01-24 | 2020-10-16 | 가톨릭대학교 산학협력단 | 간암에서 CEACAM1 및 EpCAM의 상관관계 및 이를 이용한 간암 치료효과에 대한 정보를 제공하는 방법 |
| CN114040799A (zh) * | 2019-03-12 | 2022-02-11 | 哈佛大学校长及研究员协会 | 治疗癌症的方法和组合物 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| US12564642B2 (en) | 2020-11-10 | 2026-03-03 | Sanofi | CEACAM5 antibody-drug conjugate formulation |
| WO2022116079A1 (zh) * | 2020-12-03 | 2022-06-09 | 上海吉倍生物技术有限公司 | 一种抗ceacam5的人源化抗体及其制备方法和用途 |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2024100663A1 (en) * | 2022-11-10 | 2024-05-16 | Famewave Ltd. | Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities |
| AU2023390277A1 (en) * | 2022-12-07 | 2025-05-29 | Immuneonco Biopharmaceuticals (Shanghai) Inc. | Cancer combination therapy using cd24 antibody and pd-1-pd-l1 pathway blocking antibody |
| KR20250120305A (ko) | 2022-12-14 | 2025-08-08 | 아스텔라스 파마 유럽 비.브이. | Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법 |
| WO2024151091A1 (ko) * | 2023-01-11 | 2024-07-18 | 한국과학기술원 | 종양 내 treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물 |
| CN121335923A (zh) * | 2023-04-13 | 2026-01-13 | 苏州逻晟生物医药有限公司 | Ceacam1靶向抗体及其用途 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| AR134560A1 (es) | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| HU215180B (hu) | 1992-01-23 | 1998-10-28 | Merck Patent Gmbh. | Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására |
| JP3659261B2 (ja) | 1994-10-20 | 2005-06-15 | モルフォシス・アクチェンゲゼルシャフト | 組換体タンパク質の多機能性複合体への標的化ヘテロ結合 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2222055A1 (en) | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Multimeric proteins |
| ES2246567T3 (es) | 1998-04-15 | 2006-02-16 | Brigham & Womens Hospital | Composiciones para receptores inhibidores de celulas t y usos de las mismas. |
| RU2494107C2 (ru) * | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| DE102008036127A1 (de) | 2008-08-01 | 2010-02-04 | Emitec Gesellschaft Für Emissionstechnologie Mbh | Verfahren zum Betrieb einer Abgasanlage mit Lambda-Regelung |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| AU2010225456B2 (en) * | 2009-03-18 | 2016-03-17 | Carina Biotech Pty Ltd | Biomarkers and uses thereof |
| DK2424896T3 (en) | 2009-04-30 | 2015-12-14 | Tel Hashomer Medical Res Infrastructure & Services Ltd | The anti-CEACAM1 antibodies and methods of use thereof |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| CA2916638C (en) | 2012-07-31 | 2021-01-12 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| CN104853776B (zh) * | 2012-10-12 | 2021-04-09 | 布里格姆及妇女医院股份有限公司 | 免疫应答的增强 |
-
2014
- 2014-11-25 ES ES14863190T patent/ES2808684T3/es active Active
- 2014-11-25 CA CA2930218A patent/CA2930218C/en active Active
- 2014-11-25 EP EP20151989.9A patent/EP3763387B1/en active Active
- 2014-11-25 PL PL20151989.9T patent/PL3763387T3/pl unknown
- 2014-11-25 EP EP14863190.6A patent/EP3074035B1/en active Active
- 2014-11-25 CN CN201480062823.5A patent/CN105744955B/zh active Active
- 2014-11-25 WO PCT/IL2014/051019 patent/WO2015075725A1/en not_active Ceased
- 2014-11-25 MX MX2016006726A patent/MX375221B/es active IP Right Grant
- 2014-11-25 HK HK16114541.7A patent/HK1225998A1/zh unknown
- 2014-11-25 ES ES20151989T patent/ES2980417T3/es active Active
- 2014-11-25 US US15/039,022 patent/US10081679B2/en active Active
- 2014-11-25 PL PL14863190T patent/PL3074035T3/pl unknown
- 2014-11-25 JP JP2016532636A patent/JP6879739B2/ja active Active
- 2014-11-25 RU RU2016124540A patent/RU2697522C1/ru active
- 2014-11-25 KR KR1020167015560A patent/KR102362803B1/ko active Active
- 2014-11-25 AU AU2014351308A patent/AU2014351308B2/en not_active Ceased
-
2019
- 2019-12-06 JP JP2019221240A patent/JP2020055853A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020055853A5 (https=) | ||
| JP2016537383A5 (https=) | ||
| JP2020534250A5 (https=) | ||
| JP2020103301A5 (https=) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2017048240A5 (https=) | ||
| JP2022101693A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| JP2020502271A5 (https=) | ||
| JP2021526509A5 (https=) | ||
| JP2019510733A5 (https=) | ||
| JP2019524701A5 (https=) | ||
| RU2016124540A (ru) | Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака | |
| JP2018070648A5 (https=) | ||
| JP2020507571A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2019535670A5 (https=) | ||
| JP2018512138A5 (https=) | ||
| JPWO2019246514A5 (https=) | ||
| JP2021522347A5 (https=) | ||
| JP2015172045A5 (https=) | ||
| JP2016534735A5 (https=) | ||
| JP2020528936A5 (https=) | ||
| JP2023037000A5 (https=) | ||
| JPWO2021104371A5 (https=) |